Aosaikang's subsidiary signs ASKG712 project licensing agreement
Aosaikang's holding subsidiary AskGene Pharma has signed a licensing agreement with Visara, allowing Visara to use the independently developed innovative drug ASKG712 in specific regions. This drug targets VEGF and ANG-2 and is currently undergoing Phase IIa clinical trials in China, showing good safety and efficacy. This collaboration will promote the research and commercialization of ASKG712, aligning with the company's strategic direction and is expected to have a positive impact on future performance
According to the Zhitong Finance APP, Aosaikang (002755.SZ) announced that its holding subsidiary AskGene Pharma, Inc. (referred to as "AskGene Pharma") has reached a licensing agreement with Visara, Inc. (referred to as "Visara") to grant Visara the rights to the Class 1 innovative drug ASK712 project, which has independent intellectual property rights, within the licensed area for a fee.
ASK712 is a Class 1 innovative drug independently developed by AskGene Pharma, with independent intellectual property rights, that can simultaneously target VEGF and ANG-2. While blocking the VEGF/VEGFR signaling pathway to control neovascularization, it can effectively inhibit ANG-2 signaling to improve vascular stability and reduce retinal inflammation. It is clinically used for the treatment of macular diseases and is currently in the Phase IIa clinical research stage in China. The results of the Phase I dose escalation and dose expansion show that ASK712 has good safety and efficacy. Meanwhile, preclinical data indicate that, compared to existing treatments, ASK712 has stronger binding activity to VEGF and ANG-2, which is expected to enhance efficacy while extending the dosing interval, reducing the frequency of intravitreal injections, and improving patient compliance.
This licensing agreement is beneficial for the research and commercialization process of the ASK712 project within the licensed area, and it helps the company further focus its innovative drug research and development direction on treatment areas such as digestion, oncology, anti-infection, and chronic diseases, aligning with the company's overall strategic direction. The implementation of the agreement is expected to have a positive impact on the company's future performance
